Vir Biotechnology Inc (VIR) — Cash Flow-to-Debt Ratio
Vir Biotechnology Inc (VIR) has a Cash Flow-to-Debt Ratio of -0.62x as of March 2026, meaning its operating cash flow of $-132.39 Million could theoretically repay -1% of its total liabilities ($212.82 Million) in one year. See Vir Biotechnology Inc free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Vir Biotechnology Inc Cash Flow-to-Debt Ratio (2017–2025)
Historical debt coverage capacity for Vir Biotechnology Inc across 9 annual periods. Also explore how fast is Vir Biotechnology Inc growing its equity to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Vir Biotechnology Inc (2017–2025)
Year-by-year debt coverage analysis for Vir Biotechnology Inc. For market capitalisation and broader financial context, see market value of Vir Biotechnology Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.65x | $-391.78 Million | $237.55 Million | ▲ +8.2% |
| 2024 | -1.80x | $-446.35 Million | $248.43 Million | ▲ +24.1% |
| 2023 | -2.37x | $-778.78 Million | $328.82 Million | ▼ -203.1% |
| 2022 | 2.30x | $1.66 Billion | $724.12 Million | ▲ +2621.5% |
| 2021 | -0.09x | $-47.59 Million | $522.42 Million | ▲ +90.4% |
| 2020 | -0.95x | $-190.94 Million | $201.91 Million | ▲ +35.7% |
| 2019 | -1.47x | $-129.63 Million | $88.13 Million | ▼ -479.6% |
| 2018 | -0.25x | $-94.10 Million | $370.77 Million | ▼ -22.5% |
| 2017 | -0.21x | $-66.38 Million | $320.48 Million | — |